MDV3100 is an investigational therapy in clinical development for the treatment of advanced prostate cancer. The first triple-acting, oral anti-androgen, MDV3100 has been shown in preclinical studies to provide more compIete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions – MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation), and inhibits binding to DNA. Preclinical data published in Science earlier this year demonstrated that MDV3100 is superior to bicalutamide in each of these three actions. read more at:
www.medicalnewstoday.com
More From The Farber Center for Radiation Oncology
- Breast Cancer Expert | The Farber Center for Radiation Oncology
- Find clinical trials for prostate cancer in your area
- October is National Breast Cancer Awareness Month
The Farber Center for Radiation Oncology Recommends
- The Top Five Types of Treatment for Psoriasis (stanfieldsk)
- The Fundamentals of Pure Skin Care While Dealing With Bad acne (stanfieldsk)
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
